<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02235909</url>
  </required_header>
  <id_info>
    <org_study_id>AR14.001</org_study_id>
    <nct_id>NCT02235909</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension</brief_title>
  <official_title>A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbor Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbor Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of the study drug relative to&#xD;
      an active comparator losartan which is in the same class of drug and is approved for use in&#xD;
      the pediatric population aged 6 years and older. Approximately 260 subjects will participate&#xD;
      in a 6-week, double-blind, randomized, treatment phase, followed by a 2-week, double-blind,&#xD;
      randomized, placebo-controlled withdrawal phase. A 44-week, open-label extension in which all&#xD;
      subjects will receive azilsartan and other antihypertensive medications (if needed). Blood&#xD;
      pressure will be assessed throughout the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of the study drug relative to&#xD;
      an active comparator losartan which the same class of drug and is approved for use in the&#xD;
      pediatric population aged 6 years and older. Approximately 260 subjects will participate in a&#xD;
      6-week, double-blind, randomized, treatment phase, followed by a 2-week, double-blind,&#xD;
      randomized, placebo-controlled withdrawal phase. This study also includes a 44-week,&#xD;
      open-label extension Phase in which all subjects will receive azilsartan and other&#xD;
      antihypertensive medications (if needed) in order to reach an optimal blood pressure. Blood&#xD;
      pressure will be assessed in the clinic throughout the study, and subjects may also&#xD;
      participate in a 24-hour ambulatory blood pressure monitoring procedure at baseline, at the&#xD;
      end of the double-blind Phase and at the end of the open-label Phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2014</start_date>
  <completion_date type="Actual">September 27, 2020</completion_date>
  <primary_completion_date type="Actual">November 27, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>There are 3 phases in this study. Double-blind, withdrawal phase, and open-label phase.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blind masking in the Double Blind Phase and Withdrawal Phase.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Blood Pressure</measure>
    <time_frame>Double-Blind and Withdrawal Phase</time_frame>
    <description>Change from Week 6/Final Visit of the double-blindPhase to Week 8/Final Visit of the WD Phase in trough clinic seated diastolic blood pressure between azilsartan medoxomil and placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in blood Pressure relative to the comparator</measure>
    <time_frame>Double Blind and Withdrawal Phase</time_frame>
    <description>Change from Week 6/Final Visit of the double-blind Phase to Week 8/Final Visit of the withdrawal phase in trough clinic seated systolic blood pressure and mean arterial pressure (MAP) between azilsartan medoxomil and placebo.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Double blind phase: Azilsartan Medoxomil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double blind phase; Randomized 1:1:1:1. Once a day dosing. Azilsartan medoxomil at 10 mg, or 20 mg, or 40 mg force-titrated to 80 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double blind phase: Losartan 25 or 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double blind phase: Double blind phase; Randomized 1:1:1:1. Once a day dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withdrawal Phase: Azilsartan medoxomil dose taken in Double blind phase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withdrawal Phase: Placebo to match azilsartan medoxomil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Arm In the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Label Phase: Azilsartan Medoxomil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azilsartan Medoxomil 10 mg which can be titrated to higher dose(s) (up to 40 mg for subjects &lt;50 kg or up to 80 mg for subjects ≥50 kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Label Phase: &quot;Other&quot;</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Additional antihypertension medication, as needed. Name and dose as determined by PI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withdrawal Phase: Losartan 25 or 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withdrawal Phase: Placebo to Losartan</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Arm In the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan Medoxomil</intervention_name>
    <arm_group_label>Double blind phase: Azilsartan Medoxomil</arm_group_label>
    <arm_group_label>Open Label Phase: &quot;Other&quot;</arm_group_label>
    <arm_group_label>Open Label Phase: Azilsartan Medoxomil</arm_group_label>
    <arm_group_label>Withdrawal Phase: Azilsartan medoxomil dose taken in Double blind phase</arm_group_label>
    <other_name>AZM</other_name>
    <other_name>AR14</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <arm_group_label>Double blind phase: Losartan 25 or 50 mg</arm_group_label>
    <arm_group_label>Withdrawal Phase: Losartan 25 or 50 mg</arm_group_label>
    <other_name>Cozaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Azilsartan Medoxomil</intervention_name>
    <arm_group_label>Withdrawal Phase: Placebo to match azilsartan medoxomil</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Losartan</intervention_name>
    <arm_group_label>Withdrawal Phase: Placebo to Losartan</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antihypertension medication</intervention_name>
    <description>If add-on therapy is needed, the type of medication (eg a calcium channel blocker, such as amlodipine, a diuretic, such as hydrochlorothiazide, or a beta-blocker such as metoprolol) added will be determined per the investigator's clinical judgment.&quot;. These are not predefined.</description>
    <arm_group_label>Open Label Phase: &quot;Other&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject has hypertension (primary or secondary) defined as clinic Seated Diastolic&#xD;
             BP ≥95th percentile (by age, gender, and height) or ≥90th percentile (by age, gender,&#xD;
             height) if chronic renal disease, diabetes, heart failure or hypertensive target organ&#xD;
             damage is present&#xD;
&#xD;
               1. If currently treated: The subject has a documented historical diagnosis of&#xD;
                  hypertension AND a post-washout clinic Seated Diastolic BP meeting the above&#xD;
                  criteria on Day -1 (or Day 1 for subjects not participating in Ambulatory Blood&#xD;
                  Pressure Monitoring)&#xD;
&#xD;
               2. If currently untreated: The subject has elevated Seated Diastolic BP meeting the&#xD;
                  above criteria on 3 separate occasions before Randomization, including on Day -1&#xD;
                  (or Day 1 for subjects not participating in Ambulatory Blood Pressure Monitoring)&#xD;
&#xD;
          -  The subject is male or female and aged 6 to &lt;18 years at Baseline and weighs at least&#xD;
             25 kg&#xD;
&#xD;
          -  The subject agrees to continue their previously implemented nonpharmacological life&#xD;
             style modifications if begun prior to Screening. Note: For subjects participating in a&#xD;
             weight loss program, the weight maintenance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has a clinic Seated Diastolic BP greater than 15 mm Hg and/or Seated&#xD;
             Diastolic BP greater than 10 mm Hg above the 99th percentile for age, gender, and&#xD;
             height as confirmed by the average (arithmetic mean) of 3 serial clinic seated BP&#xD;
             measurements at Screening/Visit 1&#xD;
&#xD;
          -  The subject has a diagnosis of malignant or accelerated hypertension&#xD;
&#xD;
          -  The subject is currently treated with more than 2 antihypertensive agents&#xD;
&#xD;
          -  The subject or parent/legal guardian is not willing for the subject's previous&#xD;
             antihypertensive medications to be stopped&#xD;
&#xD;
          -  The subject has participated in the intensive, active weight-loss phase of a&#xD;
             weight-loss program within 30 days prior to Screening/Visit 1&#xD;
&#xD;
          -  The subject has any of the following: severe renal impairment (eGFR &lt;30 mL/min/1.73 m2&#xD;
             by the Schwartz formula); is currently undergoing dialysis treatment; renovascular&#xD;
             disease affecting both kidneys or a solitary kidney; severe nephrotic syndrome not in&#xD;
             remission; or serum albumin &lt;2.5 g/dL&#xD;
&#xD;
          -  The subject has a history or clinical manifestations of severe cardiovascular,&#xD;
             hepato-biliary, gastrointestinal, endocrine-metabolic (e.g., hyperthyroidism,&#xD;
             Cushing's syndrome), hematologic, immunologic, genito-urinary, or psychiatric disease,&#xD;
             cancer, and/or any conditions that would interfere with the health status of the&#xD;
             subject through study participation, or would jeopardize study integrity in the&#xD;
             opinion of the investigator&#xD;
&#xD;
          -  The subject is suffering from uncorrected coarctation of the aorta, or hemodynamically&#xD;
             significant left ventricular outflow tract obstruction due to eg, aortic valvular&#xD;
             disease, or is likely to undergo a procedure known to affect blood pressure (eg,&#xD;
             repair of arterial anomalies) during the course of the study&#xD;
&#xD;
          -  The subject is poorly controlled diabetic defined as having a glycosylated hemoglobin&#xD;
             value &gt;8.5% at Screening/Visit 1&#xD;
&#xD;
          -  The subject has hyperkalemia as defined by the central laboratory's normal reference&#xD;
             range or any pertinent electrolyte disorders at Screening/Visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>steve Caras, MD</last_name>
    <role>Study Director</role>
    <affiliation>Arbor Pharmaceuticals, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Research Center, INC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Direct Helpers Research Center</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JDH Medical Group LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami/Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Center of Miami II, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Clinical Research</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Clinical Research</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zoe Center for Pediatrics</name>
      <address>
        <city>Thomaston</city>
        <state>Georgia</state>
        <zip>30286</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David M. Headley, MD PA</name>
      <address>
        <city>Port Gibson</city>
        <state>Mississippi</state>
        <zip>39150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai PRIME</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memphis and Shelby County Pediatric Group</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Texas Clinical Research Center</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Heart Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ericksen Research &amp; Development, LLC</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Columbia Research</name>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano</name>
      <address>
        <city>Ciudad Autonoma</city>
        <state>Buenos Aires</state>
        <zip>1181</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Niños</name>
      <address>
        <city>Ciudad Autonoma</city>
        <state>Buenos Aires</state>
        <zip>C1425EFD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Nefrologia, Urologia y Enf. Cardiovasculares S A</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000EPV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Nefrokids Ltda</name>
      <address>
        <city>Curitiba</city>
        <zip>80240-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas da PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiologia do Rio Grande do Sul</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90620-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação José Luiz Egydio Setúbal</name>
      <address>
        <city>São Paulo</city>
        <zip>01227-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Samaritano</name>
      <address>
        <city>São Paulo</city>
        <zip>01232-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eurolatino Pesquisas Médicas Ltda.</name>
      <address>
        <city>Uberlândia</city>
        <zip>38411-186</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHATPPD-Ruse EOOD</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Oftalmologica de Santander - FOSCAL</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Hospitalaria San Vicente de Paul</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobón Uribe</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institucion Prestadora de Servicios de Salud de la Universidad de Antioquia &quot;IPS UNIVERSITARIA&quot;</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Principal SMO Kft.</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Svabhegy Plusz Gyermekegeszsegugyi Kozpont</name>
      <address>
        <city>Budapest</city>
        <zip>1037</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Lukacs Korhaz Dombovar</name>
      <address>
        <city>Dombovar</city>
        <zip>7200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prehospital Med Kft.</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin. Kozp.</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Giovanni XXIII</name>
      <address>
        <city>Bari</city>
        <zip>70125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.R.N.A.S. Ospedale Civico e Benfratelli, G. Cristina e M.Ascoli</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Aplicadas a la Neurociencia A.C.</name>
      <address>
        <city>Durango</city>
        <zip>34000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Mexico</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelerium S. de R.L. de C.V.</name>
      <address>
        <city>Monterrey</city>
        <zip>6400</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica Chapultepec S.A. de C.V.</name>
      <address>
        <city>Morelia</city>
        <zip>58260</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa</name>
      <address>
        <city>Bialystok</city>
        <zip>15-274</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Dziecięcy w Krakowie</name>
      <address>
        <city>Krakow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ TRI-medica</name>
      <address>
        <city>Lodz</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praktyka Lekarzy Rodzinnych R.Jadach, M.Domanski NZOZ</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-072</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LCS Clinical Research Unit</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2021</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soweto Clinical Trial Centre</name>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <zip>1818</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netcare St. Anne's Hospital</name>
      <address>
        <city>Pietermaritzburg</city>
        <state>KwaZulu-Natal</state>
        <zip>3201</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital E13 Renal Unit</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Projects Research SA (PTY) LTD</name>
      <address>
        <city>Worcester</city>
        <state>Western Cape</state>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRISMO Bertha Gxowa Research Centre</name>
      <address>
        <city>Germiston</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cukurova University Medical Faculty</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gazi University Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Istanbul Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul University Medicine Faculty</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erciyes University Medical Faculty</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celal Bayar University Medical Faculty</name>
      <address>
        <city>Manisa</city>
        <zip>45040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMI Chernivtsi City Children Clinical Hospital</name>
      <address>
        <city>Chernivtsi</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Children CH Cardiology Department Kharkiv NMU</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI National Research Center of Radiation Medicine of NAMSU</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USPC of ES EO&amp;T Transplantation of MHU</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HSEI of Ukraine UMSA</name>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SSU Division MU Ch of pediatrics</name>
      <address>
        <city>Sumy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vynnitsa Regional Children CH pediatric department № 1 M.I. Pyrogov NMU</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI Zaporizhzhia City Multibranch Children Hospital #5</name>
      <address>
        <city>Zaporizhzhia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI Zaporizhzhia Regional Clinical Children Hospital of ZRC</name>
      <address>
        <city>Zaporizhzhia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 8, 2014</study_first_submitted>
  <study_first_submitted_qc>September 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2014</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric Hypertension</keyword>
  <keyword>High Blood Pressure</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Primary Hypertension</keyword>
  <keyword>Secondary Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Azilsartan medoxomil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

